title: Evolution of (18)FDG pituitary uptake after medical control of acromegaly.
authors: Department of Endocrinology and Metabolic Diseases, CHU Reunion, Groupe Hospitalier Sud-Reunion, BP 350, 97448, Saint-Pierre, France, jean-christophe.maiza@chu-reunion.fr.
authors: Jean-Christophe
authors: JC
authors: Maiza
authors: Cedric
authors: C
authors: Revel
mesh_terms: D000172:Acromegaly / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D000236:Adenoma / Q000000981:diagnostic imaging; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics; D006727:Hormone Antagonists / Q000627:therapeutic use; D006801:Humans; D010902:Pituitary Gland / Q000000981:diagnostic imaging*; D010911:Pituitary Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D010954:Plasmacytoma / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D013004:Somatostatin / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D006727:Hormone Antagonists; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D013004:Somatostatin
references: Pituitary. 2010;13(1):78-9
references: 19915981
references: Eur J Nucl Med Mol Imaging. 2010 Dec;37(12):2334-43
references: 20661556
references: Pituitary. 2012 Dec;15(4):614-5
references: 23080123